Dr. Albiruni Razak, MD
Claim this profilePrincess Margaret Cancer Centre
Area of expertise
Soft Tissue Sarcoma
Albiruni Razak, MD has run 3 trials for Soft Tissue Sarcoma. Some of their research focus areas include:
Solid Tumors
Albiruni Razak, MD has run 2 trials for Solid Tumors. Some of their research focus areas include:
Affiliated Hospitals
Princess Margaret Cancer Centre
Clinical Trials Albiruni Razak, MD is currently running
Circulating DNA Analysis
for Soft Tissue Sarcoma
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.
Recruiting
1 award
N/A
6 criteria
YL211
for Cancer
This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of three parts. Part 1 is dose-escalation part. In part 1, the safety and tolerability of YL211 in patients with selected advanced solid tumors will be evaluated and the MTD and RED will be determined. Part 2 is backfill enrollment part. We will further estimate the safety and efficacy of YL211 in patients with selected adcance tumor to select the RED(s) of YL211. Part 3 is dose-expansion part. In this part, we will further evaluate the safety and efficacy of YL211 at the MTD/RED(s) in patients with selected advanced solid tumors YL211 will be administered intravenously (IV) until criteria of treatment discontinuation are met.
Recruiting
1 award
Phase 1
2 criteria
More about Albiruni Razak, MD
Clinical Trial Related
4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Albiruni Razak, MD has experience with
- Archival Tumor Tissue Collection And Blood Draws
- Selinexor
- Pimicotinib(ABSK021)
- Placebo
- YL211
- Irinotecan Hydrochloride
Breakdown of trials Albiruni Razak, MD has run
Soft Tissue Sarcoma
Leiomyosarcoma
Endometrial Sarcoma
Uterine Leiomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Albiruni Razak, MD specialize in?
Albiruni Razak, MD focuses on Soft Tissue Sarcoma and Solid Tumors. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Albiruni Razak, MD currently recruiting for clinical trials?
Yes, Albiruni Razak, MD is currently recruiting for 2 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Albiruni Razak, MD has studied deeply?
Yes, Albiruni Razak, MD has studied treatments such as Archival tumor tissue collection and blood draws, Selinexor, Pimicotinib(ABSK021).
What is the best way to schedule an appointment with Albiruni Razak, MD?
Apply for one of the trials that Albiruni Razak, MD is conducting.
What is the office address of Albiruni Razak, MD?
The office of Albiruni Razak, MD is located at: Princess Margaret Cancer Centre, Toronto, Ontario M5G 2M9 Canada. This is the address for their practice at the Princess Margaret Cancer Centre.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.